389799-46-6 Usage
Uses
Used in Pharmaceutical Industry:
2-(4-Chloropyrimidin-5-yl)acetic acid is used as a GABA receptor ligand for its potential therapeutic applications in treating neurological disorders such as anxiety and epilepsy. Its interaction with GABA receptors may help modulate inhibitory neurotransmission, providing a potential avenue for managing these conditions.
Used in Neurological Research:
In the field of neuroscience, 2-(4-Chloropyrimidin-5-yl)acetic acid serves as a valuable research tool for studying the role of GABA receptors in the central nervous system. Its ability to interact with these receptors allows researchers to investigate the underlying mechanisms of various neurological disorders and explore potential therapeutic interventions.
Further research and testing are necessary to provide more insights into the specific effects and potential uses of 2-(4-Chloropyrimidin-5-yl)acetic acid in treating neurological conditions and its role in understanding the complex interactions within the central nervous system.
Check Digit Verification of cas no
The CAS Registry Mumber 389799-46-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,8,9,7,9 and 9 respectively; the second part has 2 digits, 4 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 389799-46:
(8*3)+(7*8)+(6*9)+(5*7)+(4*9)+(3*9)+(2*4)+(1*6)=246
246 % 10 = 6
So 389799-46-6 is a valid CAS Registry Number.
389799-46-6Relevant academic research and scientific papers
HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS
-
Page/Page column 39, (2009/10/30)
The present invention provides compounds of Formula I, pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor.
HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS
-
Page/Page column 44, (2009/10/17)
The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor.
